: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

Abstract • About • The 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF

Liver Diseases

Free Subscription

Articles published in J Hepatol
Retrieve available abstracts of 506 articles:
HTML format

Single Articles

December 2025

CHEN Y, Lee D, Kwan KK, Wu M, et al
Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.
J Hepatol. 2025;83:1338-1352.
PubMed Abstract available

HANSEN CD, Hansen JK, Israelsen M, Andersen P, et al
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.
J Hepatol. 2025;83:1278-1291.
PubMed Abstract available

PENNISI G, Di Maria G, Wong VW, de Ledinghen V, et al
Impact of first and further decompensation in patients with compensated ACLD due to MASLD.
J Hepatol. 2025;83:1266-1277.
PubMed Abstract available

OH JH, Yoon EL, Park H, Lee S, et al
Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2025;83:1256-1265.
PubMed Abstract available

DESCHLER S, Pohl-Topcu J, Ramsauer L, Meiser P, et al
Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.
J Hepatol. 2025;83:1364-1378.
PubMed Abstract available

November 2025

AGUILAR F, Lozano JJ, Claria J, Reinartz Groba SN, et al
Maladaptive emergency granulopoiesis predicts poor outcomes in patients hospitalized with decompensated cirrhosis.
J Hepatol. 2025 Nov 26:S0168-8278(25)02630-3. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

CORDIER P, Hirsch TZ, Caruso S, Pan L, et al
Intratumour Ploidy Heterogeneity and Clonal Evolution in Hepatocellular Carcinoma.
J Hepatol. 2025 Nov 24:S0168-8278(25)02654-6. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

DING K, Mao A, Wang Y, Ni Z, et al
MARCO(+) macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis.
J Hepatol. 2025 Nov 20:S0168-8278(25)02624-8. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

LI R, Zhang J, Peng J, Zhang J, et al
Divergent sex-specific trends in alcohol-attributable cirrhosis and liver cancer mortality: population-level insights complementing NHANES findings.
J Hepatol. 2025 Nov 14:S0168-8278(25)02623-6. doi: 10.1016/j.jhep.2025.
PubMed

FRANCIS H, Glaser S, Ueno Y, Lesage G, et al
Corrigendum to 'cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway' (J Hepatol 41 [2004] 528-537).
J Hepatol. 2025 Nov 7:S0168-8278(25)02563-2. doi: 10.1016/j.jhep.2025.
PubMed

JACHS M, Thone P, Odriozola A, Turon F, et al
Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.
J Hepatol. 2025 Nov 3:S0168-8278(25)02570-X. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

TORP N, Israelsen M, Thiele M, Rinella ME, et al
Phosphatidylethanol in steatotic liver disease.
J Hepatol. 2025;83:1189-1203.
PubMed Abstract available

JAECKEL E, Friedman SL, Hudecek M, Protzer U, et al
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.
J Hepatol. 2025;83:1156-1171.
PubMed Abstract available

TAVAGLIONE F, Diaz LA, Ajmera V, Madamba E, et al
Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification.
J Hepatol. 2025;83:1023-1034.
PubMed Abstract available

ALGUERO-NADAL A, Mol H, Zoppolato E, Kowalczyk W, et al
Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation.
J Hepatol. 2025;83:1142-1155.
PubMed Abstract available

LIU J, Xiao S, Hu S, Huang R, et al
Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.
J Hepatol. 2025;83:1035-1045.
PubMed Abstract available

VAZ J, Nasr P, Helander A, Shang Y, et al
Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes.
J Hepatol. 2025;83:1011-1022.
PubMed Abstract available

October 2025

LIU M, Chen M, Weng J, Xu S, et al
Hepatic LONP1 Overexpression Ameliorates Hepatic Steatosis and Fibrosis in mice.
J Hepatol. 2025 Oct 31:S0168-8278(25)02607-8. doi: 10.1016/j.jhep.2025.
PubMed

MALIK AK, White SA, Mann DA
Comment on: Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration.
J Hepatol. 2025 Oct 31:S0168-8278(25)02606-6. doi: 10.1016/j.jhep.2025.
PubMed

CUI T, Sun L, Guo X, Cheng C, et al
Corrigendum to 'Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response' (J Hepatol 2025 [946-958]).
J Hepatol. 2025 Oct 27:S0168-8278(25)02554-1. doi: 10.1016/j.jhep.2025.
PubMed

LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
Corrigendum to: "Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study" [J Hepatol (2024) 278-288].
J Hepatol. 2025 Oct 27:S0168-8278(25)02553-X. doi: 10.1016/j.jhep.2025.
PubMed

BANARES J, Pons M, Reiberger T, Mandorfer M, et al
Refining the Baveno VII criteria for clinically significant portal hypertension: an individual-patient data meta-analysis.
J Hepatol. 2025 Oct 23:S0168-8278(25)02565-6. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

GLYNN AM, Faye MD, Gerard IJ, Vanner RJ, et al
Stereotactic body radiotherapy treatment for hepatocellular carcinoma with extensive macrovascular invasion.
J Hepatol. 2025 Oct 17:S0168-8278(25)02559-0. doi: 10.1016/j.jhep.2025.
PubMed

CELSA C, Pinato DJ, Cabibbo G
"Advancing Clinical Trial Design and Patient Care in Hepatocellular Carcinoma".
J Hepatol. 2025 Oct 17:S0168-8278(25)02558-9. doi: 10.1016/j.jhep.2025.
PubMed

YUAN H, Zhao L, Yang G, Zhang S, et al
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.
J Hepatol. 2025 Oct 16:S0168-8278(25)02556-5. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

QIAN S, He Y
Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma.
J Hepatol. 2025 Oct 10:S0168-8278(25)02548-6. doi: 10.1016/j.jhep.2025.
PubMed

TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort.
J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

WEDEMEYER H, Tacke F, Newsome P, Ratziu V, et al
The first human xenogeneic liver transplantation - A landmark event, but what does it mean for hepatology?
J Hepatol. 2025 Oct 9:S0168-8278(25)02496-1. doi: 10.1016/j.jhep.2025.
PubMed

THEVENOT T, Desmarets M, Tio G
Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?
J Hepatol. 2025 Oct 9:S0168-8278(25)02551-6. doi: 10.1016/j.jhep.2025.
PubMed

GARG P, Verma N, Jalan R
Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
J Hepatol. 2025 Oct 9:S0168-8278(25)02549-8. doi: 10.1016/j.jhep.2025.
PubMed

CHEN F, Tchorz JS
Postnatal hepatocyte proliferation - challenge and opportunity for gene therapy.
J Hepatol. 2025 Oct 6:S0168-8278(25)02520-6. doi: 10.1016/j.jhep.2025.
PubMed

RUDLER M
Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial.
J Hepatol. 2025 Oct 6:S0168-8278(25)02476-6. doi: 10.1016/j.jhep.2025.
PubMed

OCHOA-ALLEMANT P, Hubbard RA, Kaplan DE, Serper M, et al
Cause-specific mortality in patients with steatotic liver disease in the United States.
J Hepatol. 2025;83:860-869.
PubMed Abstract available

DIAZ LA, Alazawi W, Agrawal S, Arab JP, et al
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.
J Hepatol. 2025;83:849-859.
PubMed Abstract available

RIMASSA L, Chan SL, Sangro B, Lau G, et al
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
J Hepatol. 2025;83:899-908.
PubMed Abstract available

ZHANG XF, Zuo XY, Zhu Y, Li JX, et al
Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma.
J Hepatol. 2025 Oct 1:S0168-8278(25)02517-6. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

September 2025

GALANAKIS V, Gribben C, Munteanu A, Cagna M, et al
Transcriptomic and epigenetic mechanisms controlling cholangiocytes transdifferentiation into hepatocytes.
J Hepatol. 2025 Sep 29:S0168-8278(25)02516-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

LISMAN T, Puente A, Garcia-Pagan JC
Anticoagulant therapy to delay disease progression in patients with cirrhosis - reponse to Acka et al., Bot et al. and Feng et al.
J Hepatol. 2025 Sep 25:S0168-8278(25)02495-X. doi: 10.1016/j.jhep.2025.
PubMed

VERMA N, Kaur P, Garg P, Ranjan V, et al
Corrigendum to "Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis" [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028].
J Hepatol. 2025 Sep 25:S0168-8278(25)02475-4. doi: 10.1016/j.jhep.2025.
PubMed

ZHANG T
RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
J Hepatol. 2025 Sep 24:S0168-8278(25)02499-7. doi: 10.1016/j.jhep.2025.
PubMed

HSU C
Engineered T cell therapy for hepatocellular carcinoma: the dawn of precision immunotherapy?
J Hepatol. 2025 Sep 23:S0168-8278(25)02491-2. doi: 10.1016/j.jhep.2025.
PubMed

MAURO E, de Castro T, Zeitlhoefler M, Hackshaw A, et al
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma.
J Hepatol. 2025 Sep 22:S0168-8278(25)02492-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

LIN YJ, Ou DL, Su YY, Hsu CL, et al
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration.
J Hepatol. 2025 Sep 17:S0168-8278(25)02471-7. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

AKCA M, Ketenci YB, Demiroz H, Avcioglu U, et al
Concerns on Rivaroxaban Use in Cirrhosis: Pharmacokinetic, Safety, and Bleeding Risk Considerations.
J Hepatol. 2025 Sep 17:S0168-8278(25)02489-4. doi: 10.1016/j.jhep.2025.
PubMed

PINATO DJ
Immunotherapy in advanced hepatocellular cancer: The last piece of the puzzle.
J Hepatol. 2025 Sep 5:S0168-8278(25)02384-0. doi: 10.1016/j.jhep.2025.
PubMed

FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].
J Hepatol. 2025 Sep 5:S0168-8278(25)02439-0. doi: 10.1016/j.jhep.2025.
PubMed

KIM HD, Sym SJ, Chon HJ, Kim M, et al
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
J Hepatol. 2025 Sep 4:S0168-8278(25)02457-2. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

ALLAIRE M, Meneghetti AR, Mouri S, Kather JN, et al
A Role of Non-Selective Beta-Blockers in Preventing Liver Decompensation in Patients with Hepatocellular Carcinoma Undergoing Systemic Therapy.
J Hepatol. 2025 Sep 3:S0168-8278(25)02469-9. doi: 10.1016/j.jhep.2025.
PubMed

ZHOU T
Optimizing Clinical Adoption of Large Language Models in Hepatology: Toward Terminological Precision, Multilingual Adaptability, and Interpretive Literacy.
J Hepatol. 2025 Sep 2:S0168-8278(25)02470-5. doi: 10.1016/j.jhep.2025.
PubMed

NEUSCHWANDER-TETRI BA, Akbary K, Carpenter DH, Noureddin M, et al
The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.
J Hepatol. 2025;83:790-799.
PubMed Abstract available

ISSA G, Shang Y, Strandberg R, Hagstrom H, et al
Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden.
J Hepatol. 2025;83:643-651.
PubMed Abstract available

August 2025

DIXON ED, Claudel T, Nardo AD, Riva A, et al
Erratum to 'Inhibition of ATGL alleviates MASH via impaired PPARa signalling that favours hydrophilic bile acid composition in mice' [J Hepatol 82 (2025) 658-675].
J Hepatol. 2025 Aug 30:S0168-8278(25)02438-9. doi: 10.1016/j.jhep.2025.
PubMed

ZHOU H, Ba J, Xiao C, Liu H, et al
Alcohol activates ATF4/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis.
J Hepatol. 2025 Aug 28:S0168-8278(25)02458-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

CHAN SL, Lamarca A, Hsu C, Moreno V, et al
New targets and new drugs for hepatobiliary cancers.
J Hepatol. 2025 Aug 25:S0168-8278(25)02455-9. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

VERMA N, Kaur P, Jalan R
Disease Staging and Clinical State in Cirrhosis: Is severity, acuity and pathophysiology the missing link?
J Hepatol. 2025 Aug 25:S0168-8278(25)02456-0. doi: 10.1016/j.jhep.2025.
PubMed

ROMERO-CRISTOBAL M
Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science.
J Hepatol. 2025 Aug 20:S0168-8278(25)02449-3. doi: 10.1016/j.jhep.2025.
PubMed

RIDOLA L, Riggio O
Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise.
J Hepatol. 2025 Aug 20:S0168-8278(25)02446-8. doi: 10.1016/j.jhep.2025.
PubMed

TRAMPERT DC
From parts to portal: Recapitulating hepatobiliary microarchitecture using multicellular organoids.
J Hepatol. 2025 Aug 20:S0168-8278(25)02346-3. doi: 10.1016/j.jhep.2025.
PubMed

VERMA N, Garg P, Kaur P, Munjal S, et al
Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis.
J Hepatol. 2025 Aug 12:S0168-8278(25)02405-5. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

MEYER T, Finn RS, Borad M, Mahipal A, et al
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
J Hepatol. 2025 Aug 12:S0168-8278(25)02404-3. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

BOT KK, Ezzafzafi S, Lantinga MA
Not all DOACs are created equal, revisiting the safety of rivaroxaban for the prevention of portal hypertension-related complications.
J Hepatol. 2025 Aug 5:S0168-8278(25)02396-7. doi: 10.1016/j.jhep.2025.
PubMed

BREVINI T, Swift L, Reynolds H, Ong J, et al
Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathy.
J Hepatol. 2025 Aug 5:S0168-8278(25)02388-8. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

ZHANG R, Su L, Fu M, Wang Z, et al
Corrigendum to: 'CD177(+) cells produce neutrophil extracellular traps that promote biliary atresia' (J Hepatol [2022] 77:1299-1310).
J Hepatol. 2025 Aug 4:S0168-8278(25)02281-0. doi: 10.1016/j.jhep.2025.
PubMed

CABIBBO G, Celsa C, Bhoori S, Reiberger T, et al
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma.
J Hepatol. 2025 Aug 2:S0168-8278(25)02386-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

PIANO S, Patidar KR, Juanola A
Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: enough, but not too much.
J Hepatol. 2025 Aug 2:S0168-8278(25)02395-5. doi: 10.1016/j.jhep.2025.
PubMed

HE J, Zhang M, Shi Y, Ji Z, et al
Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma.
J Hepatol. 2025 Aug 2:S0168-8278(25)02382-7. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

NADIM MK, Kellum JA, Durand F
From Protocol to Precision: The Evolving Diagnosis of Hepatorenal Syndrome.
J Hepatol. 2025 Aug 2:S0168-8278(25)02393-1. doi: 10.1016/j.jhep.2025.
PubMed

BJORN AB, Jensen MD, Pero A, Villadsen GE, et al
Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis.
J Hepatol. 2025 Aug 2:S0168-8278(25)02390-6. doi: 10.1016/j.jhep.2025.
PubMed

STEINBERG GR, Valvano CM, De Nardo W, Watt MJ, et al
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms.
J Hepatol. 2025;83:584-595.
PubMed Abstract available

HARRISON SA, Alkhouri N, Ortiz-Lasanta G, Rudraraju M, et al
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
J Hepatol. 2025;83:293-303.
PubMed Abstract available

STURM L, Schultheiss M, Stohr F, Labenz C, et al
Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS.
J Hepatol. 2025;83:348-357.
PubMed Abstract available

YIP TC, Lee HW, Lin H, Tsochatzis E, et al
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2025;83:304-314.
PubMed Abstract available

DING W, Meng Y, Ma J, Pang C, et al
Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions.
J Hepatol. 2025;83:426-439.
PubMed Abstract available

VERMA N, Angeli P, Jalan R
Stratification, Therapeutic Targeting and Towards Personalised Care in Cirrhosis.
J Hepatol. 2025 Aug 1:S0168-8278(25)02378-5. doi: 10.1016/j.jhep.2025.
PubMed

July 2025

RUDLER M
Simvastatin and rifaximin in patients with decompensated cirrhosis: Still a place for LIVER HOPE?
J Hepatol. 2025 Jul 30:S0168-8278(25)02323-2. doi: 10.1016/j.jhep.2025.
PubMed

PUENTE A, Turon F, Martinez J, Fortea JI, et al
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.
J Hepatol. 2025 Jul 19:S0168-8278(25)02336-0. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

LIU H, Wang J, Yao Y, Xia T, et al
Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma.
J Hepatol. 2025 Jul 17:S0168-8278(25)02344-X. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

PU X, Liu Y, Lyu Z, Zhou Y, et al
B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

CLUSMANN J, Balaguer-Montero M, Bassegoda O, Schneider CV, et al
The barriers for uptake of artificial intelligence in hepatology and how to overcome them.
J Hepatol. 2025 Jul 16:S0168-8278(25)02337-2. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

ENGEL B, Alaswad A, Campos-Murguia A, Zoodsma M, et al
Molecular signatures discriminating different types of rejection in human liver transplants.
J Hepatol. 2025 Jul 14:S0168-8278(25)02338-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

VITHAYATHIL M, Koku D, Aboagye EO, Sharma R, et al
Reply to: "Reevaluating Feature Selection in Machine Learning-Based Radiomics for Hepatocellular Carcinoma: Bridging the Gap Between Predictive Accuracy and Biological Relevance".
J Hepatol. 2025 Jul 12:S0168-8278(25)02341-4. doi: 10.1016/j.jhep.2025.
PubMed

THEVENOT T, Elkrief L, Bureau C, Bardou-Jacquet E, et al
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial.
J Hepatol. 2025 Jul 11:S0168-8278(25)02318-9. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

KWOK GW, Wing Fung TH, Yau T
Fulminant Tumour Lysis Syndrome after Nivolumab and Ipilimumab treatment for Hepatocellular Carcinoma.
J Hepatol. 2025 Jul 9:S0168-8278(25)02331-1. doi: 10.1016/j.jhep.2025.
PubMed

GUAN X, Yang Y, Li Y, Shao C, et al
Hepatic encephalopathy in a 16-year-old girl: A case of adult-onset hereditary metabolic liver disease.
J Hepatol. 2025 Jul 9:S0168-8278(25)02328-1. doi: 10.1016/j.jhep.2025.
PubMed

RAMACHANDRAN P
Hepatic stellate cells regulate multiple aspects of hepatocyte function in health and disease.
J Hepatol. 2025 Jul 7:S0168-8278(25)02248-2. doi: 10.1016/j.jhep.2025.
PubMed

ZENG Q, Patel S, Wang X, Hsieh MH, et al
Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation.
J Hepatol. 2025 Jul 4:S0168-8278(25)02320-7. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

MILANI M, Starinieri F, Beretta S, Monti M, et al
Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering.
J Hepatol. 2025 Jul 3:S0168-8278(25)02317-7. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

EASL Clinical Practice Guidelines on TIPS.
J Hepatol. 2025;83:177-210.
PubMed Abstract available

DE ZAWADZKI A, Leeming DJ, Sanyal AJ, Anstee QM, et al
Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.
J Hepatol. 2025;83:239-257.
PubMed Abstract available

POSE E, Piano S, Thiele M, Fabrellas N, et al
Moving diagnosis of liver fibrosis into the community.
J Hepatol. 2025;83:258-270.
PubMed Abstract available

WALLACE C, Gamkrelidze I, Estes C, Razavi H, et al
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.
J Hepatol. 2025;83:21-30.
PubMed Abstract available

SUN Y, Xu M, Wan HL, Ding X, et al
Spliced exon9 ADRM1 promotes liver oncogenicity via selective degradation of tumor suppressor FBXW7.
J Hepatol. 2025;83:92-104.
PubMed Abstract available

DONG R, Wang T, Dong W, Zhang H, et al
TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway.
J Hepatol. 2025;83:105-118.
PubMed Abstract available

GONCALVES T, Letrillart L, Carlier C, Boulagnon-Rombi C, et al
Dysphagia associated with portal hypertension and hepatocellular carcinoma, singular coincidence or hidden pathway?
J Hepatol. 2025;83:e13-e15.
PubMed

ALLEN AM, Kamath PS
Staging decompensated cirrhosis: Lumping, splitting, or just rearranging the deck chairs on the Titanic?
J Hepatol. 2025 Jul 1:S0168-8278(25)02198-1. doi: 10.1016/j.jhep.2025.
PubMed

June 2025

SANYAL AJ, Taubel J, Badri P, Bond S, et al
Phase 1 randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis.
J Hepatol. 2025 Jun 26:S0168-8278(25)02270-6. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

BEUERS U, Banales JM, Karpen S, Keitel V, et al
History and prospects of bile acid therapies.
J Hepatol. 2025 Jun 20:S0168-8278(25)02277-9. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

RODRIGUEZ N, Katzenstein C, O'Kula S, Kushner T, et al
Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC).
J Hepatol. 2025 Jun 18:S0168-8278(25)02249-4. doi: 10.1016/j.jhep.2025.
PubMed

CHEUK-FUNG YIP T, Wai-Sun Wong V
Reply to: "Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease" and "Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic to
J Hepatol. 2025 Jun 6:S0168-8278(25)02265-2. doi: 10.1016/j.jhep.2025.
PubMed

TRAMPERT DC
Bile acid species as hepatic T lymphocyte response modulators - when bile acids interfere with tumor growth.
J Hepatol. 2025 Jun 5:S0168-8278(25)00249-1. doi: 10.1016/j.jhep.2025.
PubMed

CINNAMON E, Stein I, Zino E, Rabinovich S, et al
RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions.
J Hepatol. 2025;82:1050-1067.
PubMed Abstract available

XIANG L, Wang G, Zhuang Y, Luo L, et al
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
J Hepatol. 2025;82:967-978.
PubMed Abstract available

INDIA-ALDANA S, Midya V, Betanzos-Robledo L, Yao M, et al
Impact of metabolism-disrupting chemicals and folic acid supplementation on liver injury and steatosis in mother-child pairs.
J Hepatol. 2025;82:956-966.
PubMed Abstract available

WANG Y, Wang J, Zhou Z, Gu Y, et al
A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2025;82:1068-1079.
PubMed Abstract available

May 2025

TAKEFUJI Y
Reevaluating Feature Selection in Machine Learning-Based Radiomics for Hepatocellular Carcinoma: Bridging the Gap Between Predictive Accuracy and Biological Relevance.
J Hepatol. 2025 May 29:S0168-8278(25)02258-5. doi: 10.1016/j.jhep.2025.
PubMed

CHEW V
Harnessing spatial immunity to predict recurrence in hepatocellular carcinoma.
J Hepatol. 2025 May 27:S0168-8278(25)00239-9. doi: 10.1016/j.jhep.2025.
PubMed

ENGELMANN C
Rethinking hepatic encephalopathy: Gut microbes, neurotoxins and the therapeutic horizon.
J Hepatol. 2025 May 27:S0168-8278(25)00295-8. doi: 10.1016/j.jhep.2025.
PubMed

ZHANG X, Shen J, Man K, Chu ESH, et al
Corrigendum to "CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis" [J Hepatol (2014) 61:1365-75].
J Hepatol. 2025 May 24:S0168-8278(25)00157-6. doi: 10.1016/j.jhep.2025.
PubMed

RUDLER M
Autologous macrophage therapy for compensated cirrhosis, some hope at the horizon.
J Hepatol. 2025 May 23:S0168-8278(25)00248-X. doi: 10.1016/j.jhep.2025.
PubMed

ISBISTER G, Chiew A, Buckley N, Harris K, et al
A non-inferiority randomised controlled trial of a Shorter Acetylcysteine Regimen for Paracetamol Overdose - the SARPO trial.
J Hepatol. 2025 May 23:S0168-8278(25)02206-8. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

GHALLAB A, Mandorfer M, Stirnimann G, Geyer J, et al
Enteronephrohepatic Circulation of Bile Acids and Therapeutic Potential of Systemic Bile Acid Transporter Inhibitors.
J Hepatol. 2025 May 23:S0168-8278(25)02207-X. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

HIRSCH TZ
Immune exclusion in hepatoblastoma: is beta-catenin to blame again?
J Hepatol. 2025 May 21:S0168-8278(25)02203-2. doi: 10.1016/j.jhep.2025.
PubMed

EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease.
J Hepatol. 2025 May 8:S0168-8278(25)00235-1. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

CHRISTAKI M, Biros D, Tsiakas I, Milionis H, et al
Carvedilol is superior to propranolol in preventing first and further decompensation, and mortality in patients with cirrhosis.
J Hepatol. 2025 May 7:S0168-8278(25)00291-0. doi: 10.1016/j.jhep.2025.
PubMed

CALES P, Canivet CM, Costentin C, Lannes A, et al
A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.
J Hepatol. 2025;82:794-804.
PubMed Abstract available

ABDURRACHIM D, Lek S, Ong CZL, Wong CK, et al
Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
J Hepatol. 2025;82:898-908.
PubMed Abstract available

TAN EY, Danpanichkul P, Yong JN, Yu Z, et al
Liver cancer in 2021: Global Burden of Disease study.
J Hepatol. 2025;82:851-860.
PubMed Abstract available

April 2025

AM FULGENZI C, Dalla Pria A, Leone AG, Celsa C, et al
Hepatocellular carcinoma in people living with HIV.
J Hepatol. 2025 Apr 30:S0168-8278(25)00287-9. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

RAN S, Zhang J, Tian F, Qian ZM, et al
Corrigendum to "Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study" [J Hepatol (2025) 10.1016/j.jhep.2024.09.033].
J Hepatol. 2025 Apr 28:S0168-8278(25)00225-9. doi: 10.1016/j.jhep.2025.
PubMed

JEONG S
Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease.
J Hepatol. 2025 Apr 22:S0168-8278(25)00250-8. doi: 10.1016/j.jhep.2025.
PubMed

ANGELI P, Labenz C, Piano S, Juanola A, et al
Albumin infusion in Hepatorenal Syndrome-Acute Kidney Injury: new evidence challenges recent consensus.
J Hepatol. 2025 Apr 16:S0168-8278(25)00238-7. doi: 10.1016/j.jhep.2025.
PubMed

REIBERGER T, Maasoumy B
Advancing our understanding of recompensated cirrhosis - the new "holy grail" of decompensated cirrhosis.
J Hepatol. 2025 Apr 16:S0168-8278(25)00241-7. doi: 10.1016/j.jhep.2025.
PubMed

VITHAYATHIL M, Koku D, Campani C, Nault JC, et al
Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma.
J Hepatol. 2025 Apr 15:S0168-8278(25)00244-2. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
PubMed

TONON M, Gagliardi R, Pompili E, Barone A, et al
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease.
J Hepatol. 2025 Apr 12:S0168-8278(25)00245-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

NAIK I, Yeo YH, Ng WH, Sheng-Kai Ma K, et al
Carvedilol is Associated with Lower Risk of Hepatic Decompensation Compared to Other Non-Selective Beta-Blockers in Cirrhosis.
J Hepatol. 2025 Apr 11:S0168-8278(25)00232-6. doi: 10.1016/j.jhep.2025.
PubMed

ALI K, Al Snih GM, Beyder A, Abdelmalek MF, et al
Peppermint Oil Associated Hepatotoxicity.
J Hepatol. 2025 Apr 9:S0168-8278(25)00230-2. doi: 10.1016/j.jhep.2025.
PubMed

SUN SS, Zhang J, Jin YP, Li L, et al
A Rare Cause of Lipid Metabolism Disorder and Cirrhosis in an Adult.
J Hepatol. 2025 Apr 9:S0168-8278(25)00227-2. doi: 10.1016/j.jhep.2025.
PubMed

ARAB JP, Diaz LA, Rehm J, Im G, et al
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease.
J Hepatol. 2025;82:744-756.
PubMed Abstract available

MEIJNIKMAN AS, Fondevila MF, Arrese M, Kisseleva T, et al
Towards more consistent models and consensual terminology in preclinical research for steatotic liver disease.
J Hepatol. 2025;82:760-766.
PubMed Abstract available

VILAR-GOMEZ E, Gawrieh S, Vuppalanchi R, Kettler C, et al
PNPLA3 rs738409, environmental factors and liver-related mortality in the US population.
J Hepatol. 2025;82:571-581.
PubMed Abstract available

BURKE L, Bernal W, Pirani T, Agarwal B, et al
Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort.
J Hepatol. 2025;82:615-621.
PubMed Abstract available

YANG X, Deng B, Zhao W, Guo Y, et al
FABP5(+) lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity.
J Hepatol. 2025;82:676-689.
PubMed Abstract available

RAN S, Zhang J, Tian F, Qian ZM, et al
Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study.
J Hepatol. 2025;82:560-570.
PubMed Abstract available

March 2025

ZHOU S, Zhang L, You Y, Yu K, et al
eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
J Hepatol. 2025 Mar 26:S0168-8278(25)00206-5. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

SHAWCROSS DL, Patel VC
FMT for Hepatic Encephalopathy? The THEMATIC Trial aims to make is a 'no brainer'.
J Hepatol. 2025 Mar 25:S0168-8278(25)00165-5. doi: 10.1016/j.jhep.2025.
PubMed

YU H, Ma Y
Reply to: "An ER Transmembrane Protein Protects Against Hepatic Ischemia-Reperfusion Injury By Inhibiting ER-phagy and Apoptosis?".
J Hepatol. 2025 Mar 21:S0168-8278(25)00170-9. doi: 10.1016/j.jhep.2025.
PubMed

SCHLEICHER EM, Karbannek H, Weinmann-Menke J, Galle PR, et al
Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury.
J Hepatol. 2025 Mar 19:S0168-8278(25)00164-3. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
Erratum to: 'Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis' [J Hepatol (2024) 80:268-281].
J Hepatol. 2025 Mar 15:S0168-8278(25)00140-0. doi: 10.1016/j.jhep.2025.
PubMed

LARSON EL, Ellias SD, Blezek DJ, Klug J, et al
Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis.
J Hepatol. 2025 Mar 13:S0168-8278(25)00139-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

LANTINGA MA, Tapper EB, Drenth JPH
Reply: Revisiting the use of albumin in patients with cirrhosis - trial design matters.
J Hepatol. 2025 Mar 12:S0168-8278(25)00161-8. doi: 10.1016/j.jhep.2025.
PubMed

VERMA N, Kaur P, Garg P, Ranjan V, et al
Clinical and Pathophysiological Characteristics of Non-acute Decompensation of Cirrhosis.
J Hepatol. 2025 Mar 6:S0168-8278(25)00137-0. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

WANG H, Guo M, Ren B, Zhang H, et al
Circadian Control of Hepatic Ischemia/Reperfusion Injury via HSD17B13-Mediated Autophagy in Hepatocytes.
J Hepatol. 2025 Mar 4:S0168-8278(25)00138-2. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

ALKHOURI N, Beyer C, Shumbayawonda E, Andersson A, et al
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH.
J Hepatol. 2025;82:438-445.
PubMed Abstract available

TELLEZ L, Rincon D, Payance A, Jaillais A, et al
Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort.
J Hepatol. 2025;82:480-489.
PubMed Abstract available

ZHONG Q, Zhou R, Huang YN, Huang RD, et al
Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.
J Hepatol. 2025;82:427-437.
PubMed Abstract available

Expression of concern to "Nitric oxide mimics transcriptional and post-translational regulation during alpha-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes" [J Hepatol. 2011 Jul;55(1):133-44].
J Hepatol. 2025;82:548.
PubMed

CASTOLDI M, Roy S, Angendohr C, Pellegrino R, et al
Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma.
J Hepatol. 2025;82:499-511.
PubMed Abstract available

February 2025

NADIM MK, Kellum JA, Durand F
Response to "Inclusion of patients with active urinary sediment in treatment of hepatorenal syndrome" by Hamadah A. and Gharaibeh K.
J Hepatol. 2025 Feb 28:S0168-8278(25)00147-3. doi: 10.1016/j.jhep.2025.
PubMed

LAU G, Abou-Alfa GK, Chan SL
Reply to: STRIDE's Efficacy and Safety in Asian Hepatocellular Carcinoma.
J Hepatol. 2025 Feb 28:S0168-8278(25)00146-1. doi: 10.1016/j.jhep.2025.
PubMed

NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

YOUNOSSI ZM, Stepanova M
Corrigendum to: 'Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease' [J Hepatol 80 (2024) 419-430].
J Hepatol. 2025 Feb 22:S0168-8278(25)00037-6. doi: 10.1016/j.jhep.2025.
PubMed

HOFER BS, Kwanten WJ, Francque S
Correspondence on "Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD" - Authors' Reply.
J Hepatol. 2025 Feb 20:S0168-8278(25)00098-4. doi: 10.1016/j.jhep.2025.
PubMed

LOHSE AW, Kamath PS, Sarin SK
The complexity of portal hypertension without (apparent) cirrhosis.
J Hepatol. 2025 Feb 19:S0168-8278(25)00088-1. doi: 10.1016/j.jhep.2025.
PubMed

ZANETTO A, Campello E, Senzolo M, Simioni P, et al
Response to: "Procedural bleeding in patients with cirrhosis: from prediction towards prevention".
J Hepatol. 2025 Feb 19:S0168-8278(25)00087-X. doi: 10.1016/j.jhep.2025.
PubMed

MA AT, Juanola A, Sole C, Gines P, et al
Revisiting the use of albumin in patients with cirrhosis - trial design matters.
J Hepatol. 2025 Feb 19:S0168-8278(25)00086-8. doi: 10.1016/j.jhep.2025.
PubMed

NI HM, Ding WX
An ER Transmembrane Protein Protects Against Hepatic Ischemia-Reperfusion Injury By Inhibiting ER-phagy and Apoptosis?
J Hepatol. 2025 Feb 19:S0168-8278(25)00094-7. doi: 10.1016/j.jhep.2025.
PubMed

LIU Z, Wei S, Jiang Y, Su W, et al
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway.
J Hepatol. 2025 Feb 11:S0168-8278(25)00079-0. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

BERTHIER A, Gheeraert C, Vinod M, Johanns M, et al
Unveiling the Molecular Legacy of Transient Insulin Resistance: Implications for Hepatic Metabolic Adaptability.
J Hepatol. 2025 Feb 11:S0168-8278(25)00080-7. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

MARTI-AGUADO D, Calleja JL, Bataller R, Crespo J, et al
Reply to: "The HDL criterion for MetALD can misclassify patients with cirrhosis".
J Hepatol. 2025 Feb 4:S0168-8278(25)00057-1. doi: 10.1016/j.jhep.2025.
PubMed

XUE X, Liu R, Cai Y, Gong L, et al
Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4.
J Hepatol. 2025 Feb 4:S0168-8278(25)00055-8. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

XU M, Zhao J, Zhu L, Ge C, et al
Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.
J Hepatol. 2025;82:277-300.
PubMed Abstract available

MARKOVIC J, Li R, Khanal R, Peng Q, et al
Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis.
J Hepatol. 2025;82:301-314.
PubMed Abstract available

ROSENSTENGLE C, Serper M, Asrani SK, Bittermann T, et al
Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal.
J Hepatol. 2025;82:268-276.
PubMed Abstract available

LIU YJ, Kimura M, Li X, Sulc J, et al
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
J Hepatol. 2025;82:174-188.
PubMed Abstract available

MUNTER D, de Faria FW, Richter M, Aranda-Pardos I, et al
Multiomic analysis uncovers a continuous spectrum of differentiation and Wnt-MDK-driven immune evasion in hepatoblastoma.
J Hepatol. 2025 Feb 1:S0168-8278(25)00068-6. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

HAN Y, Tang J, Hu P, Ren H, et al
Metabolic dysfunction-associated steatotic liver disease may increase intrahepatic interferon gene signatures in patients with chronic hepatitis B.
J Hepatol. 2025 Feb 1:S0168-8278(25)00073-X. doi: 10.1016/j.jhep.2025.
PubMed

January 2025

ZHANG Z, Geng C, Song M, Liang H, et al
Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity.
J Hepatol. 2025 Jan 30:S0168-8278(25)00064-9. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

PUGLIESE N, De Nicola S, di Tommaso L, Aghemo A, et al
Beyond Portal Hypertension: Characterizing Porto-Sinusoidal Vascular Disorder in Patients without signs of PH.
J Hepatol. 2025 Jan 29:S0168-8278(25)00058-3. doi: 10.1016/j.jhep.2025.
PubMed

VITTON V, Ouafik L, Nguyen K
HEPATIC NODULE AND RISING AFP LEVELS: COULD IT INDICATE A BENIGN CONDITION?
J Hepatol. 2025 Jan 29:S0168-8278(25)00056-X. doi: 10.1016/j.jhep.2025.
PubMed

SALEM R, Padia SA, Toskich BB, Callahan JD, et al
Radiation Segmentectomy for Early Hepatocellular Carcinoma is Curative.
J Hepatol. 2025 Jan 22:S0168-8278(25)00011-X. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

YU H, Wang C, Qian B, Yin B, et al
GRINA alleviates hepatic ischemia?reperfusion injury-induced apoptosis and ER-phagy by enhancing HRD1-mediated ATF6 ubiquitination.
J Hepatol. 2025 Jan 22:S0168-8278(25)00019-4. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

ZHU S, Liao L, Zhong Y, Liu Z, et al
Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis.
J Hepatol. 2025 Jan 22:S0168-8278(25)00014-5. doi: 10.1016/j.jhep.2025.
PubMed Abstract available

PINATO DJ
Tertiary lymphoid structure dynamics at the centre of immunotherapy response in hepatocellular carcinoma.
J Hepatol. 2025 Jan 21:S0168-8278(24)02831-9. doi: 10.1016/j.jhep.2024.
PubMed

RATZIU V, Tacke F
The Journal of Hepatology: A new team at 40.
J Hepatol. 2025 Jan 16:S0168-8278(25)00004-2. doi: 10.1016/j.jhep.2025.
PubMed

BARB D, Kalavalapalli S, Leiva EG, Bril F, et al
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
J Hepatol. 2025 Jan 15:S0168-8278(25)00002-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LISMAN T
Procedural bleeding in patients with cirrhosis: from prediction towards prevention.
J Hepatol. 2025 Jan 11:S0168-8278(25)00010-8. doi: 10.1016/j.jhep.2025.
PubMed

RUDLER M
Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy?
J Hepatol. 2025 Jan 11:S0168-8278(24)02773-9. doi: 10.1016/j.jhep.2024.
PubMed

GENG A, Brenig RG, Roux J, Lutge M, et al
Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges.
J Hepatol. 2025 Jan 10:S0168-8278(24)02818-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

BAJAJ JS, Fagan A, Gavis EA, Sterling RK, et al
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
J Hepatol. 2025 Jan 10:S0168-8278(25)00005-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

DEGASPERI E, Anolli MP, Jachs M, Reiberger T, et al
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
J Hepatol. 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

GADD VL, Ferreira-Gonzalez S, Man TY, Kilpatrick AM, et al
Host hepatocyte senescence determines the success of hepatocyte transplantation in a mouse model of liver injury.
J Hepatol. 2025 Jan 2:S0168-8278(24)02830-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CROUCHET E, Dachraoui M, Juhling F, Roehlen N, et al
Targeting the liver clock improves fibrosis by restoring TGF-beta signaling.
J Hepatol. 2025;82:120-133.
PubMed Abstract available

HARRISON SA, Browne SK, Suschak JJ, Tomah S, et al
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
J Hepatol. 2025;82:7-17.
PubMed Abstract available

REZAEE-ZAVAREH MS, Yeo YH, Wang T, Guo Z, et al
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
J Hepatol. 2025;82:107-119.
PubMed Abstract available

KRENDL FJ, Cardini B, Zoller H, Schneeberger S, et al
Leveraging normothermic liver machine perfusion as a platform for oncologic assessment in cirrhotic livers.
J Hepatol. 2025;82:e12-e14.
PubMed

December 2024

SHIN H, Hur MH, Song BG, Park SY, et al
AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B.
J Hepatol. 2024 Dec 20:S0168-8278(24)02784-3. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

GANNE-CARRIE N, Nahon P
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies.
J Hepatol. 2024 Dec 20:S0168-8278(24)02817-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CAPPUYNS S, Pique-Gili M, Esteban-Fabro R, Philips G, et al
Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
J Hepatol. 2024 Dec 19:S0168-8278(24)02771-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

IM GY, Bibireddy A, Rath S
The HDL criterion for MetALD can misclassify patients with cirrhosis.
J Hepatol. 2024 Dec 17:S0168-8278(24)02781-8. doi: 10.1016/j.jhep.2024.
PubMed

FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.
J Hepatol. 2024 Dec 17:S0168-8278(24)02772-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
J Hepatol. 2024 Dec 16:S0168-8278(24)02508-X. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ENGELMANN C
Rifaximin in cirrhosis: Is its microbiological spotless record under threat?
J Hepatol. 2024 Dec 16:S0168-8278(24)02735-1. doi: 10.1016/j.jhep.2024.
PubMed

ZANETTO A, Campello E, Bulato C, Willems R, et al
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis.
J Hepatol. 2024 Dec 11:S0168-8278(24)02762-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

GUAN Y, Huang Q
Correspondence on "Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD".
J Hepatol. 2024 Dec 4:S0168-8278(24)02750-8. doi: 10.1016/j.jhep.2024.
PubMed

DUIJZER R, Gevers TJ, Drenth JP
Response to: Highlighting the Impact of Hormonal Factors on Hepatic Cystogenesis: Implications for Pathophysiology and Clinical Practice.
J Hepatol. 2024 Dec 4:S0168-8278(24)02748-X. doi: 10.1016/j.jhep.2024.
PubMed

MARTI-AGUADO D, Calleja JL, Vilar-Gomez E, Iruzubieta P, et al
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024;81:930-940.
PubMed Abstract available

AHMED A, Cule M, Bell JD, Sattar N, et al
Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer.
J Hepatol. 2024;81:921-929.
PubMed Abstract available

BATTISTELLA S, Piazza F, Pizzi M, Zanella S, et al
From shadows to light: An unusual case of a hepatic mass.
J Hepatol. 2024;81:e261-e263.
PubMed

ANGELI P
My last Editorial as Editor-in-Chief of the Journal of Hepatology.
J Hepatol. 2024;81:918-920.
PubMed

WANG T, Chen K, Yao W, Zheng R, et al
Retraction notice to "Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance" [J Hepatol 74 (5) 2021 1038-1052].
J Hepatol. 2024;81:1100.
PubMed

November 2024

DONGELMANS EJ, Janssen HLA
Reply to "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.".
J Hepatol. 2024 Nov 29:S0168-8278(24)02746-6. doi: 10.1016/j.jhep.2024.
PubMed

HAMADAH A, Gharaibeh K
Inclusion of Patients with Active Urinary Sediment in Treatment of Hepatorenal Syndrome.
J Hepatol. 2024 Nov 29:S0168-8278(24)02743-0. doi: 10.1016/j.jhep.2024.
PubMed

MEHAL WZ, Schwabe RF
Corrigendum to: "A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease" [J Hepatol (2022) 765-767].
J Hepatol. 2024 Nov 22:S0168-8278(24)02623-0. doi: 10.1016/j.jhep.2024.
PubMed

WANG Y, Hong S, Hudson H, Kory N, et al
PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis.
J Hepatol. 2024 Nov 14:S0168-8278(24)02707-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LIU Y, Wei Y, Chen X, Huang S, et al
Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic.
J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

VANDERSCHUEREN E, Wim Laleman
Non-invasive algorithms could outperform HVPG in selecting candidates for non-selective beta-blockers in cirrhosis.
J Hepatol. 2024 Nov 13:S0168-8278(24)02711-9. doi: 10.1016/j.jhep.2024.
PubMed

HENGSTLER JG, Vartak N
Activating hepatobiliary water channels for gallstone prevention in complicated gallstone disease.
J Hepatol. 2024 Nov 12:S0168-8278(24)02704-1. doi: 10.1016/j.jhep.2024.
PubMed

GONZALEZ FJ, Xia Y
Adipose triglyceride lipase as a target for treatment of metabolic dysfunction-associated steatohepatitis: the role of hepatic and intestinal PPARalpha.
J Hepatol. 2024 Nov 12:S0168-8278(24)02703-X. doi: 10.1016/j.jhep.2024.
PubMed

HUR MH, Lee JH
Reply to "A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024.
PubMed

MON HC, Huang YH
Reply to "Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?" and "Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B".
J Hepatol. 2024 Nov 8:S0168-8278(24)02701-6. doi: 10.1016/j.jhep.2024.
PubMed

KIM HY, Rosenthal SB, Liu X, Miciano C, et al
Multi-Modal Analysis of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
J Hepatol. 2024 Nov 8:S0168-8278(24)02667-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MEHAL WZ
Corrigendum to: "From mice to humans: Unravelling the genetic levers of NASH" [J Hepatol (2020) 749-751].
J Hepatol. 2024 Nov 7:S0168-8278(24)02619-9. doi: 10.1016/j.jhep.2024.
PubMed

MUCINSKI JM, Salvador AF, Moore MP, Fordham TM, et al
Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH.
J Hepatol. 2024;81:781-793.
PubMed Abstract available

HARRISON SA, Dubourg J
Liver biopsy evaluation in MASH drug development: Think thrice, act wise.
J Hepatol. 2024;81:886-894.
PubMed Abstract available

OH JH, Ahn SB, Cho S, Nah EH, et al
Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
J Hepatol. 2024;81:772-780.
PubMed Abstract available

October 2024

OSMANI Z, Brouwer WP, Grashof DGB, Lim Y, et al
Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B.
J Hepatol. 2024 Oct 26:S0168-8278(24)02653-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CAO Z, Yao Y, Cai M, Zhang C, et al
Blood markers for type-1,-2, and -3 inflammation are associated with severity of acutely decompensated cirrhosis.
J Hepatol. 2024 Oct 25:S0168-8278(24)02649-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NADIM MK, Kellum JA, Durand F
Reply to correspondence on "Acute kidney Injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting".
J Hepatol. 2024 Oct 23:S0168-8278(24)02646-1. doi: 10.1016/j.jhep.2024.
PubMed

SAMUEL D
EASL Clinical Practice Guidelines on liver transplantation.
J Hepatol. 2024 Oct 23:S0168-8278(24)02440-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LEE S, Arefaine B, Begum N, Stamouli M, et al
Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial.
J Hepatol. 2024 Oct 22:S0168-8278(24)02635-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MEHAL WZ
Corrigendum to: "A gold mine of information from a deep dive into the liver transcriptome" [J Hepatol (2024) 540-542].
J Hepatol. 2024 Oct 22:S0168-8278(24)02620-5. doi: 10.1016/j.jhep.2024.
PubMed

LIU YC, Liaw YF
The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.
J Hepatol. 2024 Oct 18:S0168-8278(24)02638-2. doi: 10.1016/j.jhep.2024.
PubMed

RATZIU V, Scanlan TS, Bruinstroop E
Thyroid hormone receptor-beta analogs for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
J Hepatol. 2024 Oct 18:S0168-8278(24)02639-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

XIAO G, Ren H
Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B.
J Hepatol. 2024 Oct 16:S0168-8278(24)02630-8. doi: 10.1016/j.jhep.2024.
PubMed

HUANG Q, Qadri SF, Bian H, Yi X, et al
A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease.
J Hepatol. 2024 Oct 16:S0168-8278(24)02636-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ZHONG X, Ott M, Sharma AD, Balakrishnan A, et al
MicroRNA-107 - a small RNA with a big impact on cytokinesis in hepatocellular carcinoma.
J Hepatol. 2024 Oct 11:S0168-8278(24)02624-2. doi: 10.1016/j.jhep.2024.
PubMed

LU Y, Liu Y, Zuo X, Li G, et al
CXCL12(+) Tumor-associated Endothelial Cells Promote Immune Resistance in Hepatocellular Carcinoma.
J Hepatol. 2024 Oct 9:S0168-8278(24)02618-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN Y, Chen HN, Wang K, Zhang L, et al
Erratum to "Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma" [J Hepatol 70 (1) 2019 66-77].
J Hepatol. 2024 Oct 7:S0168-8278(24)02540-6. doi: 10.1016/j.jhep.2024.
PubMed

CATANIA M, Vezzoli G, Alibrandi MTS
Highlighting the Impact of Hormonal Factors on Hepatic Cystogenesis: Implications for Pathophysiology and Clinical Practice.
J Hepatol. 2024 Oct 5:S0168-8278(24)02581-9. doi: 10.1016/j.jhep.2024.
PubMed

LIU Z, Shan D, Han X
STRIDE's Efficacy and Safety in Asian Hepatocellular Carcinoma.
J Hepatol. 2024 Oct 5:S0168-8278(24)02582-0. doi: 10.1016/j.jhep.2024.
PubMed

TALANIAN M, Almeqdadi M, Chen HH
From dark bile to bright insight: A liver biopsy with advanced fibrosis and severe cholestasis.
J Hepatol. 2024;81:e147-e150.
PubMed

NAULT JC, Calderaro J, Ronot M
Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board.
J Hepatol. 2024;81:756-762.
PubMed Abstract available

TONON M, Barone A, Calvino V, Santori V, et al
Reply to: correspondance on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
J Hepatol. 2024;81:e170-e171.
PubMed

DE A, Mehta M, Duseja A
Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort.
J Hepatol. 2024;81:e162-e164.
PubMed

HENRY L, Paik JM, Younossi ZM
Reply to: Correspondence on "clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease'.
J Hepatol. 2024;81:e160-e161.
PubMed

GAWRIEH S, Vilar-Gomez E, Wilson LA, Pike F, et al
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.
J Hepatol. 2024;81:600-608.
PubMed Abstract available

SEGOVIA-ZAFRA A, Villanueva-Paz M, Serras AS, Matilla-Cabello G, et al
Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network.
J Hepatol. 2024;81:630-640.
PubMed Abstract available

YOUNOSSI ZM, Kremer AE, Swain MG, Jones D, et al
Assessment of fatigue and its impact in chronic liver disease.
J Hepatol. 2024;81:726-742.
PubMed Abstract available

LU Z, Shao W, Song J
The transition from NAFLD to MASLD and its impact on clinical practice and outcomes.
J Hepatol. 2024;81:e155-e156.
PubMed

LIU Y, Tan L
An in-depth exploration of difference and similarity between NAFLD and MASLD.
J Hepatol. 2024;81:e153-e154.
PubMed

ZHOU XD, Lonardo A, Pan CQ, Shapiro MD, et al
Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both.
J Hepatol. 2024;81:e157-e159.
PubMed

September 2024

FUCHS CD, Simbrunner B, Baumgartner M, Campell C, et al
Bile acid metabolism and signaling in liver disease.
J Hepatol. 2024 Sep 28:S0168-8278(24)02572-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

HUO X, Yu Z, Zhao F, Chen Y, et al
Hepatocyte Aquaporin 8-mediated Water Transport Facilitates Bile Dilution and Prevents Gallstone Formation in Mice.
J Hepatol. 2024 Sep 24:S0168-8278(24)02563-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

XIAO G, Ren H
A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024.
PubMed

REZAEE-ZAVAREH MS, Guo Z, Yang JD
Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries.
J Hepatol. 2024 Sep 19:S0168-8278(24)02558-3. doi: 10.1016/j.jhep.2024.
PubMed

DAJTI E, Villanueva C, Berzigotti A, Brujats A, et al
Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post-hoc analysis of the PREDESCI trial.
J Hepatol. 2024 Sep 18:S0168-8278(24)02553-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

RIMBERT A, Wargny M, Cariou B
Reply to "The association between primary hypobetalipoproteinemia and hepatic diseases: evidence from genetic studies".
J Hepatol. 2024 Sep 17:S0168-8278(24)02549-2. doi: 10.1016/j.jhep.2024.
PubMed

ZHANG XP, Hu MG, Liu R
Recognizing Significant Role of Microvascular Invasion in Postoperative Aggressive Recurrence of Early Hepatocellular Carcinoma.
J Hepatol. 2024 Sep 17:S0168-8278(24)02548-0. doi: 10.1016/j.jhep.2024.
PubMed

TABRIZIAN P, Holzner M, Ajmera V, Kim AK, et al
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.
J Hepatol. 2024 Sep 8:S0168-8278(24)02541-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MYOTERI D, Grypari IM, Schina M, Lohse A, et al
An overweight female with a history of allergies and drug-induced liver injury.
J Hepatol. 2024;81:e93-e95.
PubMed

CANCADO GGL, Deeb M, Dodington D, Hirschfield GM, et al
The liver in haematologic oncologic disorders.
J Hepatol. 2024;81:577-579.
PubMed

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
J Hepatol. 2024;81:492-542.
PubMed Abstract available

WARGNY M, Cariou B
Reply to: "Primary hypobetalipoproteinemia as a risk factor for liver complications".
J Hepatol. 2024;81:e125-e126.
PubMed

GAO J, Lan T, Kostallari E, Guo Y, et al
Angiocrine signaling in sinusoidal homeostasis and liver diseases.
J Hepatol. 2024;81:543-561.
PubMed Abstract available

KWAN AC, Wang M, Trivedi HD, Ji H, et al
Sex-specific associations of steatotic liver disease with vascular health.
J Hepatol. 2024;81:e105-e107.
PubMed

RONOT M
Improving HCC surveillance with abbreviated MRI: A call to integrate and innovate?
J Hepatol. 2024;81:376-378.
PubMed

HE L, Zheng W, Liao Y, Kong W, et al
Individuals with cardiometabolic risk factors are at higher risk for early-onset NAFLD.
J Hepatol. 2024;81:e99-e101.
PubMed

CILLO U, Nalesso F, Bertacco A, Indraccolo S, et al
Normothermic perfusion of a human tumoral liver for 17 days with concomitant extracorporeal blood purification therapy: Case description.
J Hepatol. 2024;81:e96-e98.
PubMed

KIM DH, Yoon JH, Choi MH, Lee CH, et al
Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC.
J Hepatol. 2024;81:461-470.
PubMed Abstract available

BERTOLINI A, Nguyen M, Zehra SA, Taleb SA, et al
Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.
J Hepatol. 2024;81:429-440.
PubMed Abstract available

TAN MY, Zhai XL
Primary hypobetalipoproteinemia as a risk factor for liver complications.
J Hepatol. 2024;81:e124.
PubMed

SHAN D
Expanding the dialogue: A closer look at AIH management and HCC risk.
J Hepatol. 2024;81:e129-e130.
PubMed

August 2024

DONGELMANS EJ, Hirode G, Hansen BE, Chen CH, et al
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study).
J Hepatol. 2024 Aug 31:S0168-8278(24)02493-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

KAHL S, Strassburger K, Pacini G, Trinks N, et al
Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity.
J Hepatol. 2024 Aug 30:S0168-8278(24)02490-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TORRES S, El Maimouni C, Herrera G, Fernandez J, et al
SPONTANEOUS CANDIDEMIA, A REAL INFECTION IN ADVANCED CIRRHOSIS.
J Hepatol. 2024 Aug 30:S0168-8278(24)02499-1. doi: 10.1016/j.jhep.2024.
PubMed

LV Y, Wang Q, Luo B, Bai W, et al
Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding: a prospective cohort study.
J Hepatol. 2024 Aug 22:S0168-8278(24)02485-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MAGAZ M, Giudicelli-Lett H, G Abraldes J, Nicoara-Farcau O, et al
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.
J Hepatol. 2024 Aug 22:S0168-8278(24)02481-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CUI A, Chung RT, Alatrakchi N
Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance - Reply.
J Hepatol. 2024 Aug 19:S0168-8278(24)02474-7. doi: 10.1016/j.jhep.2024.
PubMed

RAVANBAKHSH N, Genyk Y, Cheng A, Vats D, et al
Biliary Cirrhosis associated with WDR19-Related Ciliopathy in Siblings.
J Hepatol. 2024 Aug 18:S0168-8278(24)02475-9. doi: 10.1016/j.jhep.2024.
PubMed

YAO X, Song H, Shu H, Song J, et al
Asymptomatic cirrhosis in a 35-year-old female.
J Hepatol. 2024;81:e65-e67.
PubMed

TONON M, Barone A, Angeli P
Reply to: Correspondence on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
J Hepatol. 2024;81:e74-e75.
PubMed

DIAZ LA, Fuentes-Lopez E, Arab JP
Reply to: "The synergism of public health policies and social work may reduce mortality from cancer, liver disease and cardiovascular disease".
J Hepatol. 2024;81:e78-e79.
PubMed

PAN Z, Eslam M
The MASLD criteria overlook a number of adolescent patients with severe steatosis.
J Hepatol. 2024;81:e80-e81.
PubMed

KULKARNI AV, Sarin SK
Acute-on-chronic liver failure - steps towards harmonization of the definition!
J Hepatol. 2024;81:360-366.
PubMed Abstract available

THIELE M, Villesen IF, Niu L, Johansen S, et al
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases.
J Hepatol. 2024;81:345-359.
PubMed Abstract available

CASTERA L, Garteiser P, Laouenan C, Vidal-Trecan T, et al
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
J Hepatol. 2024;81:195-206.
PubMed Abstract available

DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
J Hepatol. 2024;81:238-247.
PubMed Abstract available

GUO S, Zeng J
The synergism of public health policies and social work may reduce mortality from cancer, liver disease and cardiovascular disease.
J Hepatol. 2024;81:e76-e77.
PubMed

July 2024

LAU G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, et al
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
J Hepatol. 2024 Jul 30:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

VENZIN V, Beccaria CG, Andreata F, Fumagalli V, et al
Intrahepatic immunity to hepatitis B virus.
J Hepatol. 2024 Jul 30:S0168-8278(24)00364-7. doi: 10.1016/j.jhep.2024.
PubMed

TONON M, Barone A, Angeli P
Reply to: Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
J Hepatol. 2024 Jul 29:S0168-8278(24)02434-6. doi: 10.1016/j.jhep.2024.
PubMed

MA AT, Juanola A, Sole C, Gines P, et al
Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin.
J Hepatol. 2024 Jul 29:S0168-8278(24)02422-X. doi: 10.1016/j.jhep.2024.
PubMed

DI COLA S, D'Amico G, Merli M
Reply to "Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations ".
J Hepatol. 2024 Jul 11:S0168-8278(24)02353-5. doi: 10.1016/j.jhep.2024.
PubMed

ARTRU F, Sacleux SC, Ursic-Bedoya J, Ntandja Wandji LC, et al
Long-term outcome following liver transplantation of patients with ACLF grade 3.
J Hepatol. 2024 Jul 7:S0168-8278(24)02346-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

KWON Y, Gottmann P, Wang S, Tissink J, et al
Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024 Jul 6:S0168-8278(24)02347-X. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
J Hepatol. 2024;81:e20-e21.
PubMed

CUSI K, Younossi Z, Roden M
From NAFLD to MASLD: Promise and pitfalls of a new definition.
J Hepatol. 2024;81:e18-e19.
PubMed

HE S, Luo Y, Ma W, Wang X, et al
Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis.
J Hepatol. 2024;81:135-148.
PubMed Abstract available

THORHAUGE KH, Semmler G, Johansen S, Lindvig KP, et al
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
J Hepatol. 2024;81:23-32.
PubMed Abstract available

June 2024

MENDOZA YP, Tsouka S, Semmler G, Seubnooch P, et al
Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression.
J Hepatol. 2024 Jun 27:S0168-8278(24)02334-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ROONEY M, Duduskar SN, Ghait M, Reissing J, et al
Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection.
J Hepatol. 2024 Jun 25:S0168-8278(24)02325-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ZHANG Y, Chen J, Su S
The association between primary hypobetalipoproteinemia and hepatic Diseases: evidence from genetic studies.
J Hepatol. 2024 Jun 24:S0168-8278(24)02328-6. doi: 10.1016/j.jhep.2024.
PubMed

FUSTER-ANGLADA C, Mauro E, Ferrer-Fabrega J, Caballol B, et al
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.
J Hepatol. 2024 Jun 24:S0168-8278(24)02324-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TARU V, Szabo G, Mehal W, Reiberger T, et al
Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation.
J Hepatol. 2024 Jun 20:S0168-8278(24)02322-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

PATMORE LA, Sonneveld MJ
Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024.
PubMed

SHAN D, Zhang G, Du Z
Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations.
J Hepatol. 2024 Jun 9:S0168-8278(24)02309-2. doi: 10.1016/j.jhep.2024.
PubMed

LAWITZ EJ, Fraessdorf M, Neff GW, Schattenberg JM, et al
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LI M, Bhoori S, Mehta N, Mazzaferro V, et al
Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

COLAPIETRO F, Akpinar R, Pugliese N, Di Tommaso L, et al
Unexpected diagnosis in females with abnormal liver ultrasound.
J Hepatol. 2024;80:e243-e245.
PubMed

DUIJZER R, Boerrigter MM, Gevers TJG, Drenth JPH, et al
The pathophysiology of polycystic liver disease.
J Hepatol. 2024;80:981-983.
PubMed

BROUWERS MCGJ, Cassiman D
Rare monogenic causes of steatotic liver disease masquerading as MASLD.
J Hepatol. 2024;80:e252-e253.
PubMed

HASHIDA R, Nakano D, Kawaguchi M, Younossi ZM, et al
Changing from NAFLD to MASLD: The implications for health-related quality of life data.
J Hepatol. 2024;80:e249-e251.
PubMed

NORMAN JS, Mehta N
Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
J Hepatol. 2024;80:e273-e274.
PubMed

DAI H, Zhu C, Huai Q, Xu W, et al
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
J Hepatol. 2024;80:913-927.
PubMed Abstract available

WU XN, Wang MZ, Zhang N, Zhang W, et al
Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
J Hepatol. 2024;80:928-940.
PubMed Abstract available

ZOU Z, Liu X, Yu J, Ban T, et al
Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
J Hepatol. 2024;80:834-845.
PubMed Abstract available

CABIBBO G, Celsa C, Rimassa L, Torres F, et al
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice.
J Hepatol. 2024;80:957-966.
PubMed Abstract available

PANG Y, Aberg F, Chen Z, Li L, et al
Predicting risk of chronic liver disease in Chinese adults: External validation of the CLivD score.
J Hepatol. 2024;80:e264-e266.
PubMed

HE C, Lu D, Zheng S, Xu X, et al
Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
J Hepatol. 2024;80:e287-e288.
PubMed

ZHANG Y, Liu H, Sheng B, Tham YC, et al
Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard?
J Hepatol. 2024;80:e279-e281.
PubMed

VARGHESE J, Chapiro J
ChatGPT: The transformative influence of generative AI on science and healthcare.
J Hepatol. 2024;80:977-980.
PubMed Abstract available

May 2024

LAO Y, Cui X, Xu Z, Yan H, et al
Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.
J Hepatol. 2024 May 31:S0168-8278(24)00369-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

PATERNOSTRO R, Kwanten WJ, Hofer BS, Semmler G, et al
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
J Hepatol. 2024 May 30:S0168-8278(24)00368-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

EASL Clinical Practice Guidelines on genetic cholestatic liver diseases.
J Hepatol. 2024 May 29:S0168-8278(24)00274-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ROY A, Tewari A, Sonthalia N, Chand Ghoshal U, et al
Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
J Hepatol. 2024 May 24:S0168-8278(24)00363-5. doi: 10.1016/j.jhep.2024.
PubMed

DI COLA S, D'Amico G, Caraceni P, Schepis F, et al
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHAPUS F, Giraud G, Huchon P, Roda M, et al
Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes.
J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN J, Kaya NA, Zhang Y, Kendarsari RI, et al
A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory.
J Hepatol. 2024 May 21:S0168-8278(24)00352-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

COLAPIETRO F, Lleo A
Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With Autoimmune Hepatitis?
J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024.
PubMed

Erratum to "EASL Clinical Practice Guidelines on acute-on-chronic liver failure" [J Hepatol 79 (2023) 461-491].
J Hepatol. 2024 May 20:S0168-8278(24)00164-8. doi: 10.1016/j.jhep.2024.
PubMed

FRANCQUE S, Krag A, Shawcross DL, Zelber-Sagi S, et al
A Turning point in Hepatology? EASL Reflects on the First Approved Drug for MASH.
J Hepatol. 2024 May 16:S0168-8278(24)00340-4. doi: 10.1016/j.jhep.2024.
PubMed

ZHU CX, Yan K, Chen L, Huang RR, et al
Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma.
J Hepatol. 2024 May 15:S0168-8278(24)00342-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NARDELLI S, Vizzutti F, Marra F, Schepis F, et al
Can we really advise a patient undergoing TIPS that the onset of episodic hepatic encephalopathy will not influence his/her survival?
J Hepatol. 2024 May 9:S0168-8278(24)00339-8. doi: 10.1016/j.jhep.2024.
PubMed

ZHANG Y, Xiao F, Xie R
Healthy volunteer bias for the role of genetic risk in dietary effects on hepatic steatosis, inflammation and fibrosis.
J Hepatol. 2024 May 9:S0168-8278(24)00335-0. doi: 10.1016/j.jhep.2024.
PubMed

YANG M, Zhang F, Liu K
Cirrhosis Decompensation: Clinical and Prognostic Analysis from a New Perspective.
J Hepatol. 2024 May 9:S0168-8278(24)00337-4. doi: 10.1016/j.jhep.2024.
PubMed

HARRISON SA, Rolph T, Knot M, Dubourg J, et al
FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.
J Hepatol. 2024 May 4:S0168-8278(24)00332-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ZHU B, Guo Y, Lv S, Ling X, et al
Hepatic phenotypes of EFL1-related Shwachman-Diamond syndrome in a biopsy-validated study.
J Hepatol. 2024 May 3:S0168-8278(24)00328-3. doi: 10.1016/j.jhep.2024.
PubMed

FOUAD Y, Ghazinyan H, Alboraie M, Al Khatry M, et al
Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition.
J Hepatol. 2024;80:e194-e197.
PubMed

XIAO R, Tian Y, Zhang J, Li N, et al
Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
J Hepatol. 2024;80:792-804.
PubMed Abstract available

CHOLANKERIL G, Kanwal F
Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea".
J Hepatol. 2024;80:e218-e219.
PubMed

YOUNOSSI ZM, Paik JM, Stepanova M, Ong J, et al
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
J Hepatol. 2024;80:694-701.
PubMed Abstract available

WANG Z, Xie D, Li J, Zhai Z, et al
Molecular force-induced liberation of transforming growth factor-beta remodels the spleen for ectopic liver regeneration.
J Hepatol. 2024;80:753-763.
PubMed Abstract available

SUN Z, Liu M, Guo J, Wang S, et al
BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024;80:e197-e199.
PubMed

XIAO MC, Jiang N, Chen LL, Liu F, et al
TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4alpha stability.
J Hepatol. 2024;80:778-791.
PubMed Abstract available

ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
J Hepatol. 2024;80:730-743.
PubMed Abstract available

XIAO H, Niu D, Zhang B
Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
J Hepatol. 2024;80:e207-e209.
PubMed

MA D, Li X
Methodological challenges in studying immune-suppressive neutrophils in HCC models.
J Hepatol. 2024;80:e215-e216.
PubMed

CIARDULLO S, Perseghin G
Steatotic liver disease phenotypes in the United States: The impact of alcohol consumption assessment.
J Hepatol. 2024;80:e203-e204.
PubMed

April 2024

YANG L, Niu K, Wang J, Shen W, et al
Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TAN MY, Su JH
Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
PubMed

MCGETTIGAN B, Shah V
EVERY SHERIFF NEEDS A DEPUTY: TARGETING NON-PARENCHYMAL CELLS TO TREAT HEPATIC FIBROSIS.
J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
PubMed

FU JT, Liu J, Wu WB, Chen YT, et al
Targeting EFHD2 Inhibits Interferon-gamma Signaling and Ameliorates Non-Alcoholic Steatohepatitis.
J Hepatol. 2024 Apr 24:S0168-8278(24)00277-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN K, Wang Y, Yang J, Kloting N, et al
EMC10 modulates hepatic ER stress and steatosis in an isoform specific manner.
J Hepatol. 2024 Apr 8:S0168-8278(24)00234-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

YIN K, Buttner M, Deligiannis IK, Strzelecki M, et al
Polyploidisation pleiotropically buffers ageing in hepatocytes.
J Hepatol. 2024 Apr 5:S0168-8278(24)00227-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN VL, Du X, Oliveri A, Chen Y, et al
Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
J Hepatol. 2024 Apr 4:S0168-8278(24)00230-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MOGA L, Paradis V, Bruno O, Valla D, et al
Hepatomegaly in a patient with a history of acute myeloid leukemia.
J Hepatol. 2024;80:e139-e142.
PubMed

TREVISANI F, Vitale A, Kudo M, Kulik L, et al
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal.
J Hepatol. 2024;80:661-669.
PubMed Abstract available

WANG CW, Huang PC, Dai CY, Huang JF, et al
Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric label.
J Hepatol. 2024;80:e157-e159.
PubMed

SHIRI AM, Zhang T, Bedke T, Zazara DE, et al
IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.
J Hepatol. 2024;80:634-644.
PubMed Abstract available

SUZUKI H, Tanaka T, Yamaguchi S, Miwa K, et al
Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD.
J Hepatol. 2024;80:e150-e151.
PubMed

CHEN J, Zhou H, Liu K
Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease.
J Hepatol. 2024;80:e143-e145.
PubMed

RETAT L, Webber L, Jepsen P, Martin A, et al
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study.
J Hepatol. 2024;80:543-552.
PubMed Abstract available

KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
J Hepatol. 2024;80:586-595.
PubMed Abstract available

YANG A, Zhu X, Zhang L, Ding Y, et al
Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort.
J Hepatol. 2024;80:e154-e155.
PubMed

March 2024

HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al
Erratum to 'JAK1 promotes HDV replication and is a potential target for antiviral therapy' [J Hepatol 80 (2024) 220-231].
J Hepatol. 2024 Mar 30:S0168-8278(24)00165-X. doi: 10.1016/j.jhep.2024.
PubMed

D'AMICO G, Perricone G
Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
PubMed

CHAN SL, Ryoo BY, Mo F, Chan LL, et al
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
J Hepatol. 2024 Mar 26:S0168-8278(24)00216-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

STRANDBERG R, Jepsen P, Hagstrom H
Developing and Validating Clinical Prediction Models in Hepatology-an Overview for Clinicians.
J Hepatol. 2024 Mar 24:S0168-8278(24)00213-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al
Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024.
PubMed

NADIM MK, Kellum JA, Forni L, Francoz C, et al
Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

YASHASWINI CN, Qin T, Bhattacharya D, Amor C, et al
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024 Mar 18:S0168-8278(24)00197-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

XU L, Zhang Y, Lin Z, Deng X, et al
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MA AT, Sole C, Juanola A, Escude L, et al
Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

JACHS M, Sandmann L, Hartl L, Tergast T, et al
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHOI SH, Lee BM, Kim J, Kim DY, et al
Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study.
J Hepatol. 2024 Mar 9:S0168-8278(24)00154-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

HAXHE S, Baldin P, Trefois P, Havelange V, et al
Jaundice with severe leucocytosis.
J Hepatol. 2024;80:e103-e105.
PubMed

RUSSO FP, Francque SM, Shawcross DL, Krag AA, et al
Advocating for the implementation of the new nomenclature for steatotic liver disease: A call to action for the national associations.
J Hepatol. 2024;80:384-386.
PubMed

GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
J Hepatol. 2024;80:495-504.
PubMed Abstract available

DIAZ LA, Fuentes-Lopez E, Idalsoaga F, Ayares G, et al
Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes.
J Hepatol. 2024;80:409-418.
PubMed Abstract available

GE X, Desert R, Magdaleno F, Han H, et al
Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
J Hepatol. 2024;80:482-494.
PubMed Abstract available

YOUNOSSI ZM, Alqahtani SA, Alswat K, Yilmaz Y, et al
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol. 2024;80:419-430.
PubMed Abstract available

BOESCH M, Lindhorst A, Feio-Azevedo R, Brescia P, et al
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
J Hepatol. 2024;80:397-408.
PubMed Abstract available

BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
J Hepatol. 2024;80:467-481.
PubMed Abstract available

IRUZUBIETA P, Santos-Laso A, Arias-Loste MT, Calleja JL, et al
Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.
J Hepatol. 2024;80:e121-e123.
PubMed

LEE E, Korf H, Vidal-Puig A
Reply to: "Liver-adipose tissue crosstalk in nonalcoholic fatty liver disease: the emerging role of remnant cholesterol": "BAT activation might improve NAFLD in patients, but this might require developing and/or maintaining functionally relevant level
J Hepatol. 2024;80:e112-e114.
PubMed

LARRUE H, Bureau C, D'Amico G
Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
J Hepatol. 2024;80:e109-e110.
PubMed

LIU Y, Chen M
Liver-adipose tissue crosstalk in non-alcoholic fatty liver disease: The emerging role of remnant cholesterol.
J Hepatol. 2024;80:e111-e112.
PubMed

February 2024

XIE P, Yu M, Zhang B, Yu Q, et al
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
J Hepatol. 2024 Feb 23:S0168-8278(24)00129-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

BLASZKIEWICZ J, Duncan SA
Use of stem cell-derived hepatocytes to model liver disease.
J Hepatol. 2024 Feb 15:S0168-8278(23)05306-0. doi: 10.1016/j.jhep.2023.
PubMed

CAON E, Martins M, Hodgetts H, Blanken L, et al
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NARDELLI S, Riggio O, Marra F, Gioia S, et al
Response to "Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?".
J Hepatol. 2024 Feb 14:S0168-8278(24)00122-3. doi: 10.1016/j.jhep.2024.
PubMed

DE VILLE DE GOYET J
Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
PubMed

YANG H, Jang JW
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
PubMed

ARTRU F, Reiberger T
One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
PubMed

ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

SOIN A, Lesurtel M, Clavien PA
To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
PubMed

HUANG CH, Tsai MH, Lin CY
Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
PubMed

LIU C, Guo C, Liu K
Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
PubMed

T R, J B
Endoscopic diagnosis and treatment for portal hypertension: not yet ready for clinical practice!
J Hepatol. 2024 Feb 6:S0168-8278(24)00120-X. doi: 10.1016/j.jhep.2024.
PubMed

WARGNY M, Goronflot T, Rimbert A, Boursier J, et al
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
J Hepatol. 2024 Feb 6:S0168-8278(24)00108-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

SILVA H, King JJ, Thorburn D, Luong TV, et al
A rare cause of liver fibrosis in an adult patient.
J Hepatol. 2024;80:e48-e50.
PubMed

ESLER WP, Cohen DE
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
J Hepatol. 2024;80:362-377.
PubMed Abstract available

ARORA U, Biswas S, Aggarwal S, Duseja A, et al
MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.
J Hepatol. 2024;80:e89-e91.
PubMed

DI SESSA A, Guarino S, Umano GR, Miraglia Del Giudice E, et al
MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
J Hepatol. 2024;80:e87-e89.
PubMed

PADILLA J, Osman NM, Bissig-Choisat B, Grimm SL, et al
Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
J Hepatol. 2024;80:282-292.
PubMed Abstract available

HE L, Zheng W, Qiu K, Kong W, et al
Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
J Hepatol. 2024;80:e85-e87.
PubMed

KIM D, Wijarnpreecha K, Cholankeril G, Ahmed A, et al
Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.
J Hepatol. 2024;80:e79-e81.
PubMed

JEONG S
Nutrients associated with metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024;80:e81-e82.
PubMed

CHEN L, Tao X, Zeng M, Mi Y, et al
Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
J Hepatol. 2024;80:e64-e66.
PubMed

SANAL MG
Is the change from NAFLD to MASLD driven by political correctness?
J Hepatol. 2024;80:e74-e76.
PubMed

HAGSTROM H, Vessby J, Ekstedt M, Shang Y, et al
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.
J Hepatol. 2024;80:e76-e77.
PubMed

PERAZZO H, Pacheco AG, Griep RH
Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort.
J Hepatol. 2024;80:e72-e74.
PubMed

LUO N, Zhang X, Huang J, Chen H, et al
Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
J Hepatol. 2024;80:e70-e71.
PubMed

EL-KASSAS M, Alswat K
Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
J Hepatol. 2024;80:e66-e68.
PubMed

JI H, Cheng S
Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
J Hepatol. 2024;80:e68-e69.
PubMed

SEMMLER G, Wernly B, Datz C
What's in a name? New nomenclature for steatotic liver disease - to be or not to be?
J Hepatol. 2024;80:e56-e58.
PubMed

SHIPMAN KE
Sample types and patient preparation required when adopting the new fatty liver disease nomenclature.
J Hepatol. 2024;80:e60-e61.
PubMed

DE A, Bhagat N, Mehta M, Taneja S, et al
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
J Hepatol. 2024;80:e61-e62.
PubMed

RATZIU V, Boursier J
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
J Hepatol. 2024;80:e51-e52.
PubMed

SONG SJ, Lai JC, Wong GL, Wong VW, et al
Can we use old NAFLD data under the new MASLD definition?
J Hepatol. 2024;80:e54-e56.
PubMed

LI M, Xie W
Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
J Hepatol. 2024;80:e53-e54.
PubMed

SCHNEIDER KM, Schneider CV
A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.
J Hepatol. 2024;80:e58-e60.
PubMed

ZHANG Q, Wei T, Jin W, Yan L, et al
Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
J Hepatol. 2024;80:293-308.
PubMed Abstract available

LEI Z, Yu J, Wu Y, Shen J, et al
CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.
J Hepatol. 2024;80:194-208.
PubMed Abstract available

January 2024

NING Z
An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
PubMed

CAMPION D, Caviglia GP, Alessandria C
Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
PubMed

NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
Genetic cholestasis in children and adults.
J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
PubMed

TANG R, Li Y, Chen R, Ma X, et al
Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
PubMed

TABRIZIAN P, Abdelrahim M, Schwartz M
Immunotherapy and Transplantation for Hepatocellular Carcinoma.
J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
PubMed

ESPINOZA AF, Patel RH, Patel KR, Badachhape AA, et al
A Novel Treatment Strategy Utilizing Panobinostat for High-Risk and Treatment-Refractory Hepatoblastoma.
J Hepatol. 2024 Jan 17:S0168-8278(24)00040-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHAN LL, Mok K, Chan SL
Radiotherapy following Intrahepatic Progression on Immunotherapy in Advanced Hepatocellular Carcinoma.
J Hepatol. 2024 Jan 17:S0168-8278(24)00044-8. doi: 10.1016/j.jhep.2024.
PubMed

OSONOI S, Takebe T
Organoid-guided Precision Hepatology for Metabolic Liver Disease.
J Hepatol. 2024 Jan 16:S0168-8278(24)00038-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NAKANO M, Kawaguchi M, Kawaguchi T
Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
PubMed

JACHS M, Hartl L, Simbrunner B, Semmler G, et al
Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SONG Q, Zhang X, Yu J
Reply to "Stop Using the Misidentified Cell Line - LO2 as a Human Hepatocyte".
J Hepatol. 2024 Jan 4:S0168-8278(24)00006-0. doi: 10.1016/j.jhep.2023.
PubMed

HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
PubMed

SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19].
J Hepatol. 2024 Jan 4:S0168-8278(23)05355-2. doi: 10.1016/j.jhep.2023.
PubMed

TERGAST TL, Maasoumy B
The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
PubMed

ZHENG C, Wang L, Zou T, Lian S, et al
Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.
J Hepatol. 2024;80:10-19.
PubMed Abstract available

BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
J Hepatol. 2024;80:73-81.
PubMed Abstract available

THOMAIDES-BREARS H, Banerjee R, Banerjee A
Reply to: "Reassessing the causal relationship between liver diseases and cardiovascular outcomes" and "From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank".
J Hepatol. 2024;80:e24-e25.
PubMed

KAFFE E, Tisi A, Magkrioti C, Aidinis V, et al
Bioactive signalling lipids as drivers of chronic liver diseases.
J Hepatol. 2024;80:140-154.
PubMed Abstract available

XIANG X, Wei Y, Zhao K
Reassessing the causal relationship between liver diseases and cardiovascular outcomes.
J Hepatol. 2024;80:e20-e22.
PubMed

DIAZ-FONTENLA F, Caballero-Marcos A, Peligros I, Vicario Moreno JL, et al
Unusual early post-transplant hepatic dysfunction.
J Hepatol. 2024;80:e11-e13.
PubMed

December 2023

ZHANG F, Zhang M, Wang L, Zhuge Y, et al
Hepatic encephalopathy and survival after transjugular intrahepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?
J Hepatol. 2023 Dec 26:S0168-8278(23)05368-0. doi: 10.1016/j.jhep.2023.
PubMed

NORMAN JS, Mehta N
Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
PubMed

TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

HAHN M, Herber A, Berg T, Seehofer D, et al
Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
PubMed

LEHRICH BM, Zhang J, Monga SP, Dhanasekaran R, et al
Battle of the Biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
J Hepatol. 2023 Dec 15:S0168-8278(23)05307-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
PubMed

NARDELLI S, Riggio O, Marra F, Gioia S, et al
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

FAN W, Cao D, Yang B, Wang J, et al
Hepatic prohibitin 1 and methionine adenosyltransferase alpha1 defend against primary and secondary liver cancer metastasis.
J Hepatol. 2023 Dec 2:S0168-8278(23)05298-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
A rare cause of painful hepatomegaly.
J Hepatol. 2023;79:e228-e230.
PubMed

Ending stigmatizing language in alcohol and liver disease: A liver societies' statement.
J Hepatol. 2023;79:1347-1348.
PubMed

HUTCHISON AL, Tavaglione F, Romeo S, Charlton M, et al
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
J Hepatol. 2023;79:1524-1541.
PubMed Abstract available

MOHR I, Poujois A, Ala A, Weiss KH, et al
Reply to: "Early neurological worsening in Wilson disease: The need for an evidence-based definition".
J Hepatol. 2023;79:e243.
PubMed

MENG Y, Ye F, Nie P, Zhao Q, et al
Immunosuppressive CD10(+)ALPL(+) neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.
J Hepatol. 2023;79:1435-1449.
PubMed Abstract available

PETERMANN-ROCHA F, Ho FK, Pell JP
Reply to: "Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations".
J Hepatol. 2023;79:e233-e234.
PubMed

SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
J Hepatol. 2023;79:1366-1373.
PubMed Abstract available

NEWSOME PN, Ambery P
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
J Hepatol. 2023;79:1557-1565.
PubMed Abstract available

LITWIN T, Czlonkowska A, Smolinski L
Early neurological worsening in Wilson disease: The need for an evidence-based definition.
J Hepatol. 2023;79:e241-e242.
PubMed

RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
J Hepatol. 2023;79:1542-1556.
PubMed Abstract available

LONG L, Zhou X
Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations.
J Hepatol. 2023;79:e232-e233.
PubMed

November 2023

COLASANTI O, Burm R, Huang HE, Riedl T, et al
Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
PubMed

KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
PubMed

BERASAIN C
When you eat and when you sleep matters: circadian dysfunction revealed as a direct hepatic carcinogen in a humanized mouse model.
J Hepatol. 2023 Nov 17:S0168-8278(23)05277-7. doi: 10.1016/j.jhep.2023.
PubMed

CELSA C, Cabibbo G, Am Fulgenzi C, Scheiner B, et al
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol. 2023 Nov 14:S0168-8278(23)05272-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SHAO T, Chen YL
Stop using the misidentified cell line - LO2 as a human hepatocyte.
J Hepatol. 2023 Nov 9:S0168-8278(23)05268-6. doi: 10.1016/j.jhep.2023.
PubMed

LIU J, Qian J, Yang Z, Zhou L, et al
Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
PubMed

GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

TELLEZ L, Payance A, Tjwa E, Del Cerro MJ, et al
EASL-ERN position paper on liver involvement in patients with Fontan-type circulation.
J Hepatol. 2023;79:1270-1301.
PubMed Abstract available

ROCA-FERNANDEZ A, Banerjee R, Thomaides-Brears H, Telford A, et al
Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
J Hepatol. 2023;79:1085-1095.
PubMed Abstract available

October 2023

BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
PubMed

BIBO W, Hao S, Yating W, Fucheng L, et al
Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
J Hepatol. 2023 Oct 31:S0168-8278(23)05183-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

FERNANDEZ-GARZA LE
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
PubMed

MUCKE MM, Fong S, Foster GR, Lillicrap D, et al
Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists.
J Hepatol. 2023 Oct 25:S0168-8278(23)05229-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

RATZIU V, Hompesch M, Petitjean M, Serdjebi C, et al
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.
J Hepatol. 2023 Oct 23:S0168-8278(23)05182-6. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CAMPION D, Ponzo P, Risso A, Caropreso P, et al
A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

MAIWALL R, Rao Pasupuleti SS, Sarin SK
AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
PubMed

ZHANG L, Xu J, Zhou S, Yao F, et al
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
J Hepatol. 2023 Oct 12:S0168-8278(23)05170-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CHEN X, Pan J, Zhu Y
Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
PubMed

KANG MG, Lee CH, Shen C, Kim JS, et al
Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea.
J Hepatol. 2023 Oct 10:S0168-8278(23)05166-8. doi: 10.1016/j.jhep.2023.
PubMed

SHA M, Cao J, Xia Q
Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
PubMed

CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
PubMed

GRONBAEK L, Gronbaek H
Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
PubMed

TRUSSONI CE, LaRusso NF
Macrophages make a difference in cholestatic liver diseases - but how?
J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
PubMed

ABERG F, Savikko J, Eerola V, Nordin A, et al
High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
PubMed

COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LU W
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
PubMed

GROBA SR, Soehnlein O
DRANquilizing neutrophil function in chronic liver disease.
J Hepatol. 2023;79:885-887.
PubMed

ROMERO-GOMEZ M, Lawitz E, Shankar RR, Chaudhri E, et al
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
J Hepatol. 2023;79:888-897.
PubMed Abstract available

LI L, Wang Z, Jiang Y
Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again.
J Hepatol. 2023;79:e164-e165.
PubMed

GUO R, Xu X, Babcock SA, Zhang Y, et al
Retraction notice to "Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy" [J Hepatol 62 (3) (2015) 647-656].
J Hepatol. 2023;79:1072.
PubMed

September 2023

Corrigendum to "EASL Clinical Practice Guidelines on haemochromatosis" [J Hepatol 2022 (77) 479-502].
J Hepatol. 2023 Sep 26:S0168-8278(23)05088-2. doi: 10.1016/j.jhep.2023.
PubMed

Corrigendum to "EASL clinical practice guidelines on the management of hepatic encephalopathy" [J Hepatol 2022 (77) 807-824].
J Hepatol. 2023 Sep 26:S0168-8278(23)05090-0. doi: 10.1016/j.jhep.2023.
PubMed

Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
PubMed

Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
PubMed

LALEMAN W, Vanderschueren E, Mehdi ZS, Wiest R, et al
Endoscopic procedures in HEPATOLOGY:CURRENT trends and new developments.
J Hepatol. 2023 Sep 18:S0168-8278(23)05101-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

Corrigendum to "EASL clinical practice guidelines on the management of cystic liver diseases" [J Hepatol (77) 1083-1108].
J Hepatol. 2023 Sep 17:S0168-8278(23)05089-4. doi: 10.1016/j.jhep.2023.
PubMed

CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
PubMed

NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CHEN X, Chen S, Pang J, Huang R, et al
Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.
J Hepatol. 2023 Sep 5:S0168-8278(23)05077-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

WANG Q, Bu Q, Zhou H, Lu L, et al
Reply to?"Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis".
J Hepatol. 2023 Sep 4:S0168-8278(23)05076-6. doi: 10.1016/j.jhep.2023.
PubMed

August 2023

CHEN R, Huang B, Lian M, Wei Y, et al
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

June 2023

MINAMI T, Sato M, Toyoda H, Yasuda S, et al
Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.